Elicio Therapeutics Inc
elicio.comWhat Do They Do?
Develops ready-made cancer immunotherapies for pancreatic, colorectal, and lung cancers driven by KRAS mutations.
10-K for FY2025, filed Mar 12, 2026We are a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mutant Kirsten rat…View ↗
Our lead programs focus on our cancer immunotherapy product candidates, which target biologically validated driver tumor mutations using…View ↗
Our clinical pipeline includes the lymph node targeted cancer immunotherapy ELI-002 7P, currently being evaluated in a Phase 2 study…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$8.2MView ↗
- ▼ −22% (Loss)
- vs −$10.6M in Q2 FY2025
-
Aug 13, 2026
Phase 2 trial did not meet its primary endpoint
Elicio is evaluating pre-specified subgroups to refine its Phase 3 plans for ELI-002 7P.
Sources
8-K, filed Aug 13, 2026
Reported multiple complete responses following ELI-002 7P treatment and subsequent checkpoint inhibition in metastatic mKRAS pancreatic…View ↗
From fibrosis drugs to cancer immunotherapies
The older report described small-molecule candidates for fibrotic and other diseases, while the latest report centers on ready-made, lymph-node-targeted cancer immunotherapies.
10-K for FY2022, filed Mar 17, 2023 10-K for FY2025, filed Mar 12, 2026We had been a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule…View ↗
Who Do They Compete With?
Competes with Amgen, Mirati, AstraZeneca, BioNTech, BridgeBio, Boehringer, Bristol Myers, Circio, D3 Bio, Eli Lilly, Erasca, Geneos, Gilead, Incyte, Jacobio, Jiangsu, Merck, Moderna, Revolution Medicines, and Verastem
10-K for FY2025, filed Mar 12, 2026In addition to the current standard of care treatments for patients, numerous commercial and academic preclinical studies and clinical…View ↗
Loading...
